JP2018506964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506964A5 JP2018506964A5 JP2017535814A JP2017535814A JP2018506964A5 JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5 JP 2017535814 A JP2017535814 A JP 2017535814A JP 2017535814 A JP2017535814 A JP 2017535814A JP 2018506964 A5 JP2018506964 A5 JP 2018506964A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- cell
- heavy chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 239000002157 polynucleotide Substances 0.000 claims description 23
- 102000040430 polynucleotide Human genes 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000004671 cell-free system Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000007502 anemia Diseases 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 5
- 102000004195 Isomerases Human genes 0.000 claims description 4
- 108090000769 Isomerases Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims description 3
- 206010057249 Phagocytosis Diseases 0.000 claims description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims description 3
- 230000035931 haemagglutination Effects 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000008782 phagocytosis Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- -1 E or D Chemical class 0.000 claims description 2
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 102000044459 human CD47 Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 101150036449 SIRPA gene Proteins 0.000 claims 1
- 238000010276 construction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098291P | 2014-12-30 | 2014-12-30 | |
| US62/098,291 | 2014-12-30 | ||
| PCT/US2015/067642 WO2016109415A1 (en) | 2014-12-30 | 2015-12-28 | Anti-cd47 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Division JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506964A JP2018506964A (ja) | 2018-03-15 |
| JP2018506964A5 true JP2018506964A5 (enExample) | 2019-05-23 |
| JP6850255B2 JP6850255B2 (ja) | 2021-03-31 |
Family
ID=56284963
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535814A Expired - Fee Related JP6850255B2 (ja) | 2014-12-30 | 2015-12-28 | 抗−ｃｄ４７抗体及びその使用 |
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199312A Pending JP2021048858A (ja) | 2014-12-30 | 2020-12-01 | 抗−ｃｄ４７抗体及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10870699B2 (enExample) |
| EP (1) | EP3240569A4 (enExample) |
| JP (2) | JP6850255B2 (enExample) |
| KR (1) | KR102489471B1 (enExample) |
| CN (1) | CN107530421B (enExample) |
| AU (1) | AU2015374301B2 (enExample) |
| BR (1) | BR112017014258A2 (enExample) |
| CA (1) | CA2972604C (enExample) |
| CL (1) | CL2017001736A1 (enExample) |
| CO (1) | CO2017007673A2 (enExample) |
| EA (1) | EA037654B1 (enExample) |
| EC (1) | ECSP17041865A (enExample) |
| HK (1) | HK1245154A1 (enExample) |
| MX (1) | MX391051B (enExample) |
| SG (2) | SG11201705310TA (enExample) |
| WO (1) | WO2016109415A1 (enExample) |
| ZA (1) | ZA201704467B (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037654B1 (ru) | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
| SG11201708334RA (en) * | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112019000166A2 (pt) * | 2016-07-06 | 2019-10-01 | Celgene Corp | anticorpos com baixa imunogenicidade e usos dos mesmos |
| PE20190576A1 (es) | 2016-09-29 | 2019-04-22 | Beijing Hanmi Pharmaceutical Co Ltd | Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas |
| SG11201903514VA (en) | 2016-10-20 | 2019-05-30 | I Mab | Novel cd47 monoclonal antibodies and uses thereof |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| WO2018089508A2 (en) * | 2016-11-08 | 2018-05-17 | Ablexis, Llc | Anti-cd47 antibodies |
| MX2019005858A (es) | 2016-11-18 | 2019-08-12 | Beijing Hanmi Pharmaceutical Co Ltd | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo. |
| KR102607101B1 (ko) * | 2017-01-26 | 2023-11-29 | 제트엘아이피 홀딩 리미티드 | Cd47 항원 결합 유닛 및 그것의 사용 |
| CN110300603B (zh) * | 2017-02-14 | 2023-04-14 | 亘喜生物科技（上海）有限公司 | Cd47-car-t细胞 |
| KR20190133198A (ko) * | 2017-03-27 | 2019-12-02 | 셀진 코포레이션 | 면역원성의 감소를 위한 방법 및 조성물 |
| CN110770345A (zh) | 2017-04-14 | 2020-02-07 | 托尔奈公司 | 免疫调节多核苷酸、抗体缀合物及其使用方法 |
| CA3071860A1 (en) * | 2017-08-02 | 2019-02-07 | Phanes Therapeutics, Inc. | Anti-cd47 antibodies and uses thereof |
| EP4435008A2 (en) | 2017-08-18 | 2024-09-25 | Centessa Pharmaceuticals (UK) Limited | Binding agents |
| KR20220028157A (ko) * | 2017-11-10 | 2022-03-08 | 아이-맵 바이오파마 유에스 리미티드 | Cd47 항체 및 사이토카인을 포함하는 융합 단백질 |
| BR112020009805A2 (pt) | 2017-12-01 | 2020-10-13 | Seattle Genetics, Inc. | antígeno do mesmo que liga especificamente cd47 humano, o anticorpo ou fragmento de ligação a antígeno, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos para produzir o anticorpo ou fragmento de ligação a antígeno, para tratar um câncer que expressa cd47 num indivíduo e para induzir apoptose de uma célula que expressa cd47, e, anticorpo mascarado |
| AU2018378529A1 (en) | 2017-12-04 | 2020-06-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-L1/anti-CD47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof |
| KR20200116109A (ko) * | 2018-01-24 | 2020-10-08 | 난징 레전드 바이오테크 씨오., 엘티디. | 상당한 적혈구 응집을 야기하지 않는 항-cd47 항체 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN110577597B (zh) | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技（成都）有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
| CN112566662A (zh) * | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | 针对cd47的阻断抗体及其使用方法 |
| CN112601544A (zh) * | 2018-07-05 | 2021-04-02 | 三钰生物科技股份有限公司 | 人类抗cd47抗体及其用途 |
| CN110872348B (zh) * | 2018-09-03 | 2021-09-03 | 长春金赛药业有限责任公司 | 人源化抗cd47单克隆抗体及其应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MX2021004779A (es) * | 2018-10-31 | 2021-06-08 | I Mab Biopharma Us Ltd | Anticuerpos cd47 novedosos y metodos para usarlos. |
| BR112021017399A2 (pt) | 2019-03-06 | 2021-11-16 | Jiangsu Hengrui Medicine Co | Proteína de fusão bifuncional e uso farmacêutico da mesma |
| TW202045550A (zh) | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CN112516301B (zh) * | 2019-09-17 | 2025-03-18 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体的液体制剂及其制备方法 |
| CA3153501A1 (en) | 2019-10-18 | 2021-04-22 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599681B (zh) * | 2019-10-25 | 2024-01-09 | 上海药明生物技术有限公司 | 新型抗cd47抗体及其用途 |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| EP4445902A3 (en) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| EP4110830A4 (en) | 2020-02-28 | 2024-09-11 | Tallac Therapeutics, Inc. | TRANSGLUTAMINASE-MEDIATED CONJUGATION |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| JP2023531678A (ja) | 2020-06-22 | 2023-07-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 加齢筋肉、萎縮性筋肉、または異栄養性筋肉の処置のためのｔｓｐ－１阻害物質 |
| KR20230033647A (ko) | 2020-06-30 | 2023-03-08 | 멘두스 비.브이. | 난소암 백신에서 백혈병 유래 세포의 용도 |
| CN114057876B (zh) * | 2020-07-31 | 2025-03-21 | 百奥泰生物制药股份有限公司 | Cd47抗体及其应用 |
| EP4211156A1 (en) * | 2020-09-14 | 2023-07-19 | Sutro Biopharma, Inc. | Method for large scale production of antibodies using a cell-free protein synthesis system |
| WO2022076987A1 (en) | 2020-10-07 | 2022-04-14 | Celgene Corporation | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
| WO2022120286A1 (en) | 2020-12-06 | 2022-06-09 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| TW202413428A (zh) * | 2020-12-23 | 2024-04-01 | 大陸商廣東菲鵬製藥股份有限公司 桃園路1號10棟301室 郵編：523808 | 靶向cd47的抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物、其應用及其試劑盒 |
| CN116761823A (zh) * | 2021-01-05 | 2023-09-15 | 北京生命科学研究所 | 靶向gpc3和cd47的双特异性抗体 |
| KR20230129481A (ko) * | 2021-01-08 | 2023-09-08 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Cd47과 특이적으로 결합하는 항체 및 그 항원 결합단편 |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| CR20230585A (es) | 2021-06-23 | 2024-02-19 | Gilead Sciences Inc | Compuestos Moduladores de Diacilglicerol Quinasa. |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| TWI857377B (zh) | 2021-10-28 | 2024-10-01 | 美商基利科學股份有限公司 | 嗒-3(2h)-酮衍生物 |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| JP2025513258A (ja) | 2022-04-21 | 2025-04-24 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａ ｇ１２ｄ調節化合物 |
| WO2024005423A1 (ko) * | 2022-06-29 | 2024-01-04 | 고려대학교 산학협력단 | 인간 FCγRS 결합력이 제거된 당화 FC 변이체들 |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| CA3260982A1 (en) * | 2022-07-10 | 2024-01-18 | Mbrace Therapeutics, Inc. | Cell-free processes for the production of recombinant antibodies |
| JP2025523043A (ja) | 2022-07-12 | 2025-07-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| TW202440151A (zh) | 2022-12-09 | 2024-10-16 | 美商輝瑞大藥廠 | Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法 |
| JP2025540215A (ja) | 2022-12-09 | 2025-12-11 | ファイザー・インク | Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025179135A1 (en) * | 2024-02-23 | 2025-08-28 | Board Of Regents, The University Of Texas System | Methods and compositions for treating cancer using targeted pore-forming agents |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK1233987T3 (da) | 1999-11-29 | 2009-09-28 | Bac Ip B V | Immobiliserede enkelt-domæne antigenbindende molekyler |
| EP2298809A3 (en) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Super humanized antibodies |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| JP2010524846A (ja) * | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2011004847A1 (ja) | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα９インテグリン抗体 |
| WO2011034969A1 (en) | 2009-09-15 | 2011-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| CN103635490A (zh) * | 2011-06-16 | 2014-03-12 | 诺瓦提斯公司 | 用作治疗剂的可溶性蛋白 |
| EP3766511A1 (en) * | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| CN104271757B (zh) * | 2012-02-06 | 2020-06-09 | 印希彼有限公司 | Cd47抗体及其使用方法 |
| US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| EP2953643B1 (en) * | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| SG11201508642WA (en) * | 2013-04-19 | 2015-11-27 | Sutro Biopharma Inc | Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones |
| EA037654B1 (ru) | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
| UA126146C2 (uk) | 2015-09-18 | 2022-08-25 | Арч Онколоджі, Інк. | Терапевтичне антитіло до cd47 |
| EP3353209B1 (en) | 2015-09-21 | 2022-03-16 | Erasmus University Medical Center Rotterdam | Anti-cd47 antibodies and methods of use |
-
2015
- 2015-12-28 EA EA201791485A patent/EA037654B1/ru unknown
- 2015-12-28 HK HK18104961.7A patent/HK1245154A1/zh unknown
- 2015-12-28 JP JP2017535814A patent/JP6850255B2/ja not_active Expired - Fee Related
- 2015-12-28 WO PCT/US2015/067642 patent/WO2016109415A1/en not_active Ceased
- 2015-12-28 EP EP15876093.4A patent/EP3240569A4/en not_active Withdrawn
- 2015-12-28 CN CN201580077136.5A patent/CN107530421B/zh not_active Expired - Fee Related
- 2015-12-28 US US15/541,003 patent/US10870699B2/en active Active
- 2015-12-28 SG SG11201705310TA patent/SG11201705310TA/en unknown
- 2015-12-28 CA CA2972604A patent/CA2972604C/en active Active
- 2015-12-28 SG SG10202007176TA patent/SG10202007176TA/en unknown
- 2015-12-28 KR KR1020177021330A patent/KR102489471B1/ko active Active
- 2015-12-28 BR BR112017014258A patent/BR112017014258A2/pt not_active IP Right Cessation
- 2015-12-28 MX MX2017008819A patent/MX391051B/es unknown
- 2015-12-28 AU AU2015374301A patent/AU2015374301B2/en not_active Ceased
-
2017
- 2017-06-29 CL CL2017001736A patent/CL2017001736A1/es unknown
- 2017-06-30 ZA ZA2017/04467A patent/ZA201704467B/en unknown
- 2017-06-30 EC ECIEPI201741865A patent/ECSP17041865A/es unknown
- 2017-07-28 CO CONC2017/0007673A patent/CO2017007673A2/es unknown
-
2020
- 2020-10-29 US US16/949,459 patent/US11787860B2/en active Active
- 2020-12-01 JP JP2020199312A patent/JP2021048858A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506964A5 (enExample) | ||
| US20220226469A1 (en) | Therapeutic sirp-alpha antibodies | |
| US20190263904A1 (en) | Cd3 binding antibodies | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| JP2013515508A5 (enExample) | ||
| JP2012526558A5 (enExample) | ||
| TW202208429A (zh) | 用於治療多發性骨髓瘤之方法 | |
| JP2020502233A5 (enExample) | ||
| JP2013519690A5 (enExample) | ||
| IL301330A (en) | CD47-CD38 bispecific antibodies | |
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| JPWO2019223733A5 (enExample) | ||
| CA3029977A1 (en) | Antibodies with low immunogenicity and uses thereof | |
| WO2025085854A1 (en) | Sirp antibodies for treatment of hemophagocytic lymphohistiocytosis | |
| JPWO2019141732A5 (enExample) | ||
| WO2014072741A1 (en) | Humanised antibody and method of production thereof | |
| US10640576B2 (en) | Cell engaging binding molecules | |
| WO2025085857A1 (en) | Sirp antibodies for treatment of cancer | |
| CN117120478A (zh) | 一种抗原结合分子 | |
| WO2024073482A1 (en) | Multispecific antibodies and methods of use thereof | |
| CN116462764A (zh) | 靶向cd47和her2的多特异性抗体及其用途 | |
| JPWO2021052349A5 (enExample) | ||
| WO2025226685A1 (en) | Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections | |
| US20240141062A1 (en) | Cd47-cd38 bispecific antibodies | |
| TW202547858A (zh) | 用於治療愛潑斯坦—巴爾病毒感染之ＳＩＲＰα及β抗體 |